1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCompetitive opportunity for organizations to address the harms of the opioid and overdose crisis in Maryland.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Nonprofits providing non-billable services or serving disproportionately impacted populations. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 15, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
2027 Opioid Restitution Fund Grant Program is funded by Maryland Office of Opioid Overdose Prevention. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
The August 31, 2026 award announcement splits $77 million across ten programs — $22.2 million to prevention, $23.6 million to treatment and recovery, $21.8 million to community mental health, $9.4 million to suicide and crisis. Read against the proposed consolidation of SAMHSA into the Administration for a Healthy America, the breakdown is a priorities map.
Read articleHHS has obligated roughly half a percent of the FY2026 Teen Pregnancy Prevention appropriation with days left before September 30. Here is the full timeline, the replacement NOFO that closed in July, the August court ruling, and what grantees should be doing right now.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article